BHRC BLOG
Tesamorelin + Ipamorelin Blend: Dosage, Ratios & Protocol
BHRC · Peptide & Growth-Hormone Research · Tesamorelin + Ipamorelin
Tesamorelin + Ipamorelin Blend: Dosage, Ratios & Protocol
If growth-hormone peptides had a “power couple,” this would be it. Tesamorelin + Ipamorelin pairs two compounds that raise your own growth hormone through two different doors — and the reason people stack them is simple: together they produce a bigger, cleaner GH pulse than either does alone. Tesamorelin brings the one thing that’s actually FDA-backed (visceral-fat reduction); ipamorelin adds a selective GH boost without the cortisol baggage. This guide covers how the blend works, the real dosing and ratios, timing and cycling, and the honest safety picture — all the way through to how to do it under proper medical supervision.
- Tesamorelin — a GHRH analog; drives GH/IGF-1 and reduces visceral fat.
- Ipamorelin — a selective GH secretagogue; adds a clean GH pulse, minimal cortisol.
- Why blend: two receptors, one bigger pulse — up to 2–3× more GH than either alone.
- Route: subcutaneous injection; timed before bed, fasted.
- Status: tesamorelin FDA-approved (HIV lipodystrophy); blend use is off-label, medically supervised.
1 · Meet the Two Peptides
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). It binds GHRH receptors on the anterior pituitary and prompts your body to release its own growth hormone in natural pulses; that GH then raises IGF-1 and, importantly, promotes the breakdown of visceral (deep abdominal) fat. A clever chemical tweak makes it resistant to enzyme breakdown, so it lasts long enough to work.
Ipamorelin comes at GH from the other direction. It’s a selective growth-hormone secretagogue — a ghrelin mimetic that hits the GHS-R1a receptor to trigger a GH pulse. Its claim to fame (since its original 1998 characterization) is selectivity: it releases GH without meaningfully raising cortisol or prolactin, unlike older secretagogues. Clean is the operative word.
2 · Why Blend Them? (The Synergy)
Here’s the logic. Tesamorelin activates the GHRH receptor; ipamorelin activates the ghrelin (GHS) receptor. Because those are two independent switches on the same GH-release machinery, hitting both at once produces a synergistic pulse — research on GHRH + secretagogue pairings describes roughly 2–3× greater GH release than either compound alone, while keeping the release pulsatile and physiologic rather than a flat, artificial flood.
Tesamorelin’s job
Set the stage with a strong GHRH signal — plus the visceral-fat effect it’s actually approved for.
Ipamorelin’s job
Amplify the same pulse through a different receptor, without cortisol or prolactin spikes.
The result
A larger, cleaner, more natural GH pulse than a single peptide delivers.
3 · What the Research Actually Shows
This is where honesty separates good clinics from hype. Here’s the evidence tier by tier:
- Tesamorelin (strong, FDA-level): in large randomized trials, daily tesamorelin reduced visceral fat by ~11–18% versus placebo and improved lipid profiles in patients with HIV-associated abdominal fat — the basis for its FDA approval (EGRIFTA).
- Ipamorelin (mechanistically solid): established as the first selective GH secretagogue, reliably releasing GH without the cortisol/prolactin rise seen with older GHRPs.
- The blend for “anti-aging / body comp” (weaker): the specific combination for general body composition, recovery, or longevity in healthy adults is largely off-label and not backed by large human trials — the rationale is mechanistic and anecdotal, not FDA-proven.
4 · Dosage, Ratios & Reconstitution
Because blended body-composition use is off-label, there’s no official dose — the figures below reflect commonly referenced research protocols, for education only. Your provider sets what’s right for you.
| Detail | Commonly referenced |
|---|---|
| Tesamorelin dose | ~1–2 mg/day SubQ (FDA dose for its approved use is 2 mg) |
| Ipamorelin dose | ~100–300 mcg per dose, 1–2× daily |
| Common blend ratios | 1:1 (5 mg/5 mg) · higher-tesamorelin (10 mg/3 mg) |
| Route | Subcutaneous injection (small insulin syringe) |
| Reconstitution | Lyophilized powder reconstituted with bacteriostatic water; refrigerate after mixing |
Reconstitution and dosing math are exactly the kind of thing you don’t want to freelance. A supervised program hands you the correct concentration, an accurate unit-per-dose, and someone to call — which is safer and, honestly, less stressful.
5 · Timing & Cycling
GH secretagogues have two timing rules that matter:
- Empty stomach. Food — especially carbs and fat — blunts the GH pulse. Dose with a ~2-hour fasting window around injection.
- Before bed is prime time. Dosing at night rides your body’s largest natural GH pulse, which happens in early sleep.
For cycling, a common pattern is 5 days on / 2 days off during a 8–12 week cycle, followed by a break. The off-days and cycle breaks are about keeping receptors responsive and creating checkpoints to reassess results and labs with your provider.
6 · Safety, Side Effects & Status
Raising growth hormone isn’t free of trade-offs, which is exactly why this belongs under medical supervision with lab monitoring (IGF-1, glucose):
- Common, GH-related: fluid retention/puffiness, joint aches, tingling or carpal-tunnel-like symptoms, injection-site reactions.
- Metabolic: GH can raise blood sugar / reduce insulin sensitivity — glucose should be monitored, especially in prediabetes/diabetes.
- Do not use with active malignancy, during pregnancy or breastfeeding, or without provider evaluation.
- Status: tesamorelin is FDA-approved only for HIV-associated lipodystrophy; ipamorelin is not FDA-approved; compounded blends for body composition are off-label and research-informed.
7 · Where It Fits — Stacking & Alternatives
In a supervised plan, the blend is often considered alongside — or compared with — related options:
- Tesamorelin + Ipamorelin + MOTS-c — BHRC’s blend that adds the mitochondrial peptide MOTS-c for the metabolic/energy angle.
- CJC-1295 + Ipamorelin — a popular alternative GHRH + secretagogue pairing; and Sermorelin as a gentler GHRH.
- Medical weight loss and diet/training — the fundamentals GH peptides support, not replace.
New to this category? Start with what peptides are and our best peptides for weight loss roundup.
Talk to a BHRC provider first — free. In a complimentary consultation we’ll review your goals and labs, explain what’s realistic (and what isn’t), and build a safe, physician-supervised plan with the right dosing, ratios, and monitoring. No pressure, no guesswork.
Book Your Free Consultation with a Provider →Frequently Asked Questions
What is the Tesamorelin + Ipamorelin blend?
It’s a combination of two growth-hormone peptides. Tesamorelin is a GHRH analog that stimulates your pituitary to release GH and reduces visceral fat; ipamorelin is a selective GH secretagogue that adds a clean GH pulse through a different receptor. Blended, they raise growth hormone more than either alone.
Why combine tesamorelin and ipamorelin?
They act on two different receptors — GHRH and ghrelin (GHS) — so using both produces a synergistic GH pulse, described in research on GHRH + secretagogue pairings as roughly 2–3× greater than either compound alone, while keeping release pulsatile and physiologic.
What’s the typical dosage and ratio?
There’s no official body-composition dose. Commonly referenced protocols use ~1 mg tesamorelin plus ~100–300 mcg ipamorelin, subcutaneously. Blend vials come in ratios like 1:1 (5 mg/5 mg) or higher-tesamorelin (10 mg/3 mg). Your provider confirms the right dose and ratio for you.
When should I inject it?
Before bed on an empty stomach is ideal — food (especially carbs) blunts the GH pulse, and nighttime dosing rides your body’s largest natural GH release. Some protocols use an AM and PM dose. Keep about a two-hour fasting window around each injection.
How do I cycle it?
A common pattern is 5 days on / 2 days off during an 8–12 week cycle, then a break. This helps keep receptors responsive and creates natural checkpoints to reassess results and labs with your provider.
Does it help with fat loss?
Tesamorelin has strong, FDA-recognized data for reducing visceral (deep abdominal) fat — but specifically in HIV-associated lipodystrophy. For general fat loss or body composition in healthy adults, the blend is off-label and not proven in large trials, so expectations should be realistic and provider-guided.
What are the side effects?
Because it raises GH, possible effects include fluid retention or puffiness, joint aches, tingling or carpal-tunnel-like symptoms, and injection-site reactions. GH can also raise blood sugar and reduce insulin sensitivity, so glucose and IGF-1 should be monitored — particularly with prediabetes or diabetes.
Is it FDA-approved?
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy (brand EGRIFTA). Ipamorelin is not FDA-approved. Compounded tesamorelin/ipamorelin blends for body composition are off-label and should be used only under medical supervision.
Who should not use it?
Avoid it with active cancer, during pregnancy or breastfeeding, and without a provider’s evaluation. Anyone with blood-sugar issues needs careful monitoring. A consultation and labs determine whether it’s appropriate.
How do I start safely?
Through a physician-supervised program. BHRC provides pharmaceutical-grade peptides after a consultation and lab review, with correct reconstitution, dosing, ratios, and ongoing monitoring — book a free consultation to see if it fits your goals.
Keep Reading — Peptide & GH Guides
- Tesamorelin — Visceral Fat & GH
- Ipamorelin — Selective GH Secretagogue
- CJC-1295 + Ipamorelin
- The Best Peptides for Weight Loss
- What Are Peptides? A Beginner’s Guide
Peptide Therapy Near You — BHRC Locations
Physician-supervised growth-hormone and peptide programs are available at BHRC studios nationwide, including our main six:
- Peptide & GH therapy in West Hollywood, CA
- Peptide therapy in West Los Angeles, CA
- Peptide & recovery therapy in Valencia, CA
- Peptide & GH therapy in Westlake Village, CA
- Peptide therapy in Summerlin / Las Vegas, NV
- Peptide & GH therapy in Paradise Valley / Phoenix, AZ
References & Further Reading
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med (2007). pubmed.ncbi.nlm.nih.gov
- Falutz J, et al. Tesamorelin in HIV patients with excess abdominal fat: pooled phase-3 analysis. J Clin Endocrinol Metab (2010). pubmed.ncbi.nlm.nih.gov
- Stanley TL, et al. Reduction in visceral adiposity is associated with an improved metabolic profile with tesamorelin. pubmed.ncbi.nlm.nih.gov
- Predictors of treatment response to tesamorelin (PMC). ncbi.nlm.nih.gov
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol (1998). pubmed.ncbi.nlm.nih.gov
Beverly Hills Rejuvenation Center. This content is for general education and does not create a physician-patient relationship or constitute medical advice. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; ipamorelin is not FDA-approved, and compounded tesamorelin/ipamorelin blends for body composition or anti-aging are off-label. Any use should occur only under the supervision of a licensed provider after individual evaluation and appropriate lab monitoring. Statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Reviewed by the BHRC clinical team; information current as of August 2026.
